TGFB1 and colorectal carcinoma: In a study by Tauriello et al., researchers developed human-like mouse models of metastatic colorectal cancer (CRC) and show that TGFβ1 inhibition could synergize with anti-PD-L1 therapy to exert robust T cell responses against metastatic disease8.